Detalles de la búsqueda
1.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab
; 2024 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38764356
2.
Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
Diabetes Obes Metab
; 23(12): 2614-2622, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34338409
3.
Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring.
Clin Exp Hypertens
; 41(7): 637-644, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373408
4.
Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.
BMC Endocr Disord
; 15: 34, 2015 Jul 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26137940
5.
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Front Pharmacol
; 15: 1358573, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38601470
6.
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Diab Vasc Dis Res
; 20(6): 14791641231222837, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38096503
7.
Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study.
Diabetes Ther
; 13(2): 265-274, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34988917
8.
Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Diabetes Res Clin Pract
; 185: 109231, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131376
9.
Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
J Diabetes Investig
; 12(1): 74-81, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32506833
10.
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Diabetes Technol Ther
; 23(2): 110-119, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32721227
11.
A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes.
J Clin Med Res
; 12(3): 200-208, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32231757
12.
Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study.
Diabetes Technol Ther
; 22(3): 228-234, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32013567
13.
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
J Diabetes Investig
; 11(5): 1248-1257, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32149469
14.
Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus.
J Clin Med Res
; 11(9): 651-663, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31523339
15.
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
J Diabetes Res
; 2019: 9415313, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31781668
16.
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Diab Vasc Dis Res
; 16(1): 103-107, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30284913
17.
Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.
J Clin Med Res
; 11(5): 311-320, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31019624
18.
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
J Clin Med Res
; 9(7): 586-595, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28611859
19.
Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
J Clin Med Res
; 9(9): 793-801, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28811858
20.
Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.
J Clin Med Res
; 8(2): 130-40, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26767082